Meyer Michel Samama
Overview
Explore the profile of Meyer Michel Samama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
911
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Samama M, Conard J, Mathieux V, Gerotziafas G, Horellou M, Elalamy I
Turk J Haematol
. 2016 Jun;
19(4):445-51.
PMID: 27265185
No abstract available.
2.
Samama M, Meddahi S, Samama C
Clin Lab Med
. 2014 Aug;
34(3):503-17.
PMID: 25168939
New oral factor Xa inhibitors are intended to progressively substitute the oral vitamin K antagonists and parenteral indirect inhibitors of factor Xa in the prevention and treatment of venous and...
3.
Samama M, Contant G, Spiro T, Perzborn E, Le Flem L, Guinet C, et al.
Thromb J
. 2013 Jul;
11(1):11.
PMID: 23822763
Research into new anticoagulants for preventing and treating thromboembolic disorders has focused on targeting single enzymes in the coagulation cascade, particularly Factor Xa and thrombin, inhibition of which greatly decreases...
4.
Lindhoff-Last E, Ansell J, Spiro T, Samama M
Ann Med
. 2013 Jun;
45(5-6):423-9.
PMID: 23746003
A number of target-specific oral anticoagulants (TSOAs) have been developed in recent years, and some have shown considerable promise in large-scale, randomized clinical trials in the prevention and treatment of...
5.
Samama M, Guinet C, Le Flem L, Ninin E, Debue J
J Thromb Thrombolysis
. 2013 Jan;
35(2):140-6.
PMID: 23335022
No routine coagulation laboratory test is recommended during rivaroxaban or dabigatran treatment. However measuring drug concentration and/or anticoagulant activity can be desirable in some special clinical settings, such as bleeding,...
6.
Samama M, Guinet C, Le Flem L
Thromb Res
. 2012 Oct;
130 Suppl 1:S88-9.
PMID: 23026675
Although no laboratory monitoring is needed for new anticoagulants, the measurement of their activity is required in special clinical situations. Standardised tests have been developed for rivaroxaban and dabigatran which...
7.
Seghatchian J, Samama M
Transfus Apher Sci
. 2012 Jul;
47(2):235-43.
PMID: 22770808
Massive transfusion (MT) is an empiric mode of treatment advocated for uncontrolled bleeding and massive haemorrhage, aiming at optimal resuscitation and aggressive correction of coagulopathy. Conventional guidelines recommend early administration...
8.
9.
Samama M, Contant G, Spiro T, Perzborn E, Le Flem L, Guinet C, et al.
Clin Appl Thromb Hemost
. 2012 Mar;
18(2):150-8.
PMID: 22387577
This study evaluated the prothrombin time (PT) assay for the measurement of plasma concentrations of rivaroxaban using calibrators and controls. The intra- and interlaboratory precision of the measurement was investigated...
10.
Garcia D, Baglin T, Weitz J, Samama M
Chest
. 2012 Feb;
141(2 Suppl):e24S-e43S.
PMID: 22315264
This article describes the pharmacology of approved parenteral anticoagulants. These include the indirect anticoagulants, unfractionated heparin (UFH), low-molecular-weight heparins (LMWHs), fondaparinux, and danaparoid, as well as the direct thrombin inhibitors...